Group 1: Financial Performance - The company expects a significant turnaround in 2025, with a substantial increase in net profit and net profit excluding non-recurring items compared to 2024, driven by international market expansion and cost control measures [2][3] - The overall operating costs were effectively controlled in 2025, with total expenses significantly reduced compared to the same period in 2024 [3] Group 2: Market Expansion - The company has made breakthroughs in overseas markets, particularly in Southeast Asia, the Middle East, and the Americas, leading to a notable increase in the proportion of international business in overall operations [2][4] - The international sales and service team has expanded, establishing localized sales and service points in over 20 key countries and regions [4] Group 3: Product Development and Innovation - The company has consistently focused on technological innovation, with R&D investment among the highest in the industry, launching new products such as continuous BFS and fully automated inspection machines [7] - Future strategies will continue to prioritize dual advancements in product technology and manufacturing technology, enhancing overall solution capabilities for clients in the pharmaceutical industry [7] Group 4: Strategic Outlook for 2026 - The company aims to further expand its overseas market presence, capitalizing on the growth and high-end transformation trends in the domestic pharmaceutical equipment industry [8] - Management strategies will focus on quality improvement and efficiency enhancement through smart manufacturing and cost control measures [8]